Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort

Alessandro Lazzaro; Elio Gentilini Cacciola; Cristian Borrazzo; Giuseppe Pietro Innocenti; Eugenio Nelson Cavallari; Ivano Mezzaroma; Mario Falciano; Caterina Fimiani; Claudio Maria Mastroianni; Giancarlo Ceccarelli; Gabriella d’Ettorre

doi:10.3390/diagnostics12010076

Diagnostics (Dec 2021)

Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort

Alessandro Lazzaro,
Elio Gentilini Cacciola,
Cristian Borrazzo,
Giuseppe Pietro Innocenti,
Eugenio Nelson Cavallari,
Ivano Mezzaroma,
Mario Falciano,
Caterina Fimiani,
Claudio Maria Mastroianni,
Giancarlo Ceccarelli,
Gabriella d’Ettorre

Affiliations

Alessandro Lazzaro: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy
Elio Gentilini Cacciola: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy
Cristian Borrazzo: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy
Giuseppe Pietro Innocenti: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy
Eugenio Nelson Cavallari: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy
Ivano Mezzaroma: Department of Translational and Precision Medicine, Sapienza University of Rome, AOU Policlinico Umberto I of Rome, 00185 Rome, Italy
Mario Falciano: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy
Caterina Fimiani: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy
Claudio Maria Mastroianni: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy
Giancarlo Ceccarelli: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy
Gabriella d’Ettorre: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy

DOI: https://doi.org/10.3390/diagnostics12010076
Journal volume & issue: Vol. 12, no. 1
p. 76

Abstract

Read online

Bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) is a recommended once-daily single tablet regimen for the treatment of people living with HIV-1 (PLWH). We aimed to assess efficacy, safety and tolerability of BIC/FTC/TAF among PLWH, with a specific focus on people older than 55 years. Thus, we recruited an observational retrospective real-life cohort including all PLWH who underwent a therapeutic switch to BIC/FTC/TAF, independently from the provenience treatment regimen. After 48 weeks of follow-up, 147 PLWH were included and 93 were older than 55 years. PLWH with HIV-RNA p + T cells count by 30.1% (p-value + T cells count by 7.1% (p-value = 0.004) and in CD4+/CD8+ ratio by 21.5% (p-value p-value p-value = 0.007). Total body weight increased by 1.8% (p-value = 0.014) and BMI by 4.2% (p-value < 0.001), even remaining within the healthy range. Hepatic and renal profile were not altered by the switch, nor were adverse events and/or discontinuations events detected. In conclusion, BIC/FTC/TAF is effective, safe and well tolerated in real life and among PLWH older than 55.

Published in Diagnostics

ISSN: 2075-4418 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Medicine (General)
Website: http://www.mdpi.com/journal/diagnostics

About the journal

Abstract

Keywords